News related to
prove no

Arabian Post Staff -Dubai A proposed $300 billion private investment fund has become the most sensitive economic element in the US-Iran framework agreement, with more than half of the target committed as Washington and Tehran prepare for a formal signing ceremony on Friday. The vehicle, described by a person with direct knowledge as the Reconstruction and Development Fund, is intended to create a commercial incentive for both […]

How Iqoniko and Van Sterling Capital Are Enabling Private Investors to Participate in a Growth Story via the Innovative Platform Intokia.com Lehmann Hotel und Gaststätten Holding GmbH is leveraging an innovative Capital Roadshow for digitized profit participation rights—a modern investment vehicle—as it begins its Taco Bell rollout in Bavaria, Germany. In collaboration with Iqoniko and Van Sterling, the group is establishing a model that provides both professional […]

Elon Musk’s personal fortune of $1.3 trillion exposes a flaw in one of investing’s most widely accepted ideas. The financial advice industry has for decades championed diversification as the answer to almost every investment challenge. Build a broad portfolio, spread risk, own the market and stay patient. Indeed, it’s sensible advice and, for many investors, entirely appropriate. Yet diversification has gradually evolved from a risk-management tool into […]

HANOI, VIETNAM – Media OutReach Newswire – 16 June 2026 – Vietnam National Chemical Group (Vinachem) has been recognized for the first time in the 2026 Fortune Southeast Asia 500 (Fortune SEA 500) ranking, marking a significant milestone in the Group’s development journey and reaffirming its position as one of Vietnam’s leading industrial corporations on the regional economic landscape.

Vinachem Recognized In The 2026 Fortune Southeast Asia 500 Ranking

According to Fortune, Vinachem ranked 148 among Southeast Asia’s 500 largest companies in 2026. This marks the third year that Fortune has published the Southeast Asia 500 ranking, recognizing companies that demonstrate scale, operational excellence, and significant contributions to regional economic development. The list ranks companies based on total revenue across seven countries in the region, including Vietnam, Indonesia, Thailand, Malaysia, Singapore, the Philippines, and Cambodia.

Based on Fortune’s report, Vinachem recorded revenue of USD 2.332 billion and profit of USD 103.8 million in 2025. These results reflect the Group’s solid financial foundation, resilience in responding to market fluctuations, and the effectiveness of its restructuring and productivity improvement efforts across the organization.

Mr. Nguyen Huu Tu, Chief Executive Officer of Vietnam National Chemical Group (Vinachem), said:”Vinachem’s inclusion in the Fortune Southeast Asia 500 ranking as early as 2026 represents a significant milestone in the Group’s development journey. It is a tangible outcome of our determined efforts to implement the directives set forth by the Politburo in Resolution No. 79-NQ/TW dated January 6, 2026, which aims to have 50 state-owned enterprises ranked among Southeast Asia’s 500 largest companies by 2030.

This recognition not only acknowledges the efforts of nearly 20,000 employees, engineers, and workers across Vinachem in driving innovation, transformation, and sustainable development, but also reflects the growing competitiveness of Vietnamese industrial enterprises in the regional integration process.

The achievement provides further momentum for Vinachem to accelerate innovation, digital transformation, green transition, and the development of high-tech industries. At the same time, it reinforces our commitment to fulfilling our role as a core enterprise of Vietnam’s chemical industry and contributing to the goal of building large-scale, efficient, and internationally competitive state-owned economic groups in line with the spirit of Politburo Resolution No. 79-NQ/TW.”

The development of the VinachemMart e-commerce platform and the launch of the Vinachem Agriculture platform represent concrete steps in implementing this strategy. While VinachemMart contributes to advancing digital commerce and strengthening market connectivity, Vinachem Agriculture seeks to connect farmers with scientists, experts, businesses, and government agencies, thereby improving the efficiency of the agricultural value chain and promoting green and sustainable agricultural development.

Looking ahead, Vinachem has identified innovation, digital transformation, green transition, and sustainable development as its key growth drivers. The Group is prioritizing investment in high-value, technology-intensive sectors, including pharmaceutical chemicals, advanced materials, chemicals serving the electronics and semiconductor industries, rare-earth extraction and processing, and circular economy initiatives. In parallel, Vinachem is investing in research and development (R&D) centers and integrated industrial parks designed around modern, circular, and sustainable principles, contributing to the enhanced competitiveness of Vietnam’s chemical industry within regional and global value chains.

Vinachem’s inclusion in the Fortune Southeast Asia 500 reflects not only the Group’s scale and financial strength, but also the progress achieved through its transformation, international integration, and efforts to elevate the standing of Vietnam’s chemical industry. This recognition provides a solid foundation for the Group to continue fulfilling its role as a leading enterprise, contributing to national industrial development and strengthening the presence of Vietnamese enterprises on the regional economic stage.

Hashtag: #Vinachem

The issuer is solely responsible for the content of this announcement.

By Asad Mirza The framework peace agreement between the United States and Iran has reduced the immediate risk of a wider regional war. Yet the accord leaves unresolved the central issues that have fuelled four decades of confrontation, making its long-term survival far from assured. The announcement of a framework peace agreement between the United […]

The article Can The US-Iran Peace Deal End Decades Of Hostility In West Asia? appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

Oxford physicists have demonstrated a new class of Schrödinger’s cat-like quantum states, pushing laboratory control of quantum superposition beyond the familiar model of two classical-looking wave packets held in a fragile balance. The advance, published in Physical Review X on 3 June, shows that cat-like states can be built from components that are already strongly quantum, rather than from the coherent states traditionally used to mimic the […]

The West Synchrony™ Prefillable Syringe (PFS) System offers strategic infrastructure to support Chinese biotech innovators to expand their global footprint in biologics and vaccines.

SHANGHAI, CHINA – Media OutReach Newswire – 16 June 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a long-standing partner to China’s pharmaceutical industry, today announced the availability of its West Synchrony™ prefillable syringe (PFS) system to drug developers at CPHI & PMEC China 2026, taking place June 16-18, 2026. This innovative platform uniquely integrates the syringe barrel, plunger, and needle shield/tip cap into a fully harmonized, verified system from a single supplier and emphasizes the company’s commitment to supporting the development of China’s biopharmaceutical sector in alignment with the country’s 15th Five-Year Plan. By strengthening the innovation ecosystem and accelerating development and time to market, the company supports China’s biopharmaceutical companies in achieving biotechnology breakthroughs and reaching global milestones.

West Pharmaceutical Services, Booth N5D18, CPHI & PMEC China 2026
West Pharmaceutical Services, Booth N5D18, CPHI & PMEC China 2026


Enabling China’s Next Phase of Global Biopharmaceutical Growth

China’s biopharmaceutical sector is entering a new phase of global relevance. Long recognized as a strategic pillar of the national economy, sustained policy support and investment over the past decade have helped build deep scientific capabilities and a rapidly maturing innovation ecosystem.

As more biopharmaceutical companies “Go Global”, many are establishing a growing international footprint, while others are accelerating their overseas ambitions. Emerging as core players on the global stage, Chinese companies accounted for nearly 50%1 of all new drug molecules entering human trials in the first half of 2025 alone.

At the same time, the growing complexity of biologics and vaccines is driving increased demand for advanced, high-quality drug delivery and packaging systems that can support product performance and safety from early development through commercialization. Competing globally also requires navigating stringent regulatory environments while ensuring reliable, scalable supply. Together, these factors make trusted partners with proven technical expertise and international regulatory experience critical for sustainable growth.

To support Chinese biopharmaceutical companies in their ambitions, West has now made the West Synchrony™ PFS system available in the country.

West Synchrony™ PFS System
West Synchrony™ PFS System

This gives Chinese innovators the infrastructure needed to compete on quality, safety, and regulatory compliance across international markets, with greater confidence and efficiency.

“Chinese biopharmaceutical companies today have established themselves as serious global innovators, with significant opportunities to sustain momentum through high‑quality innovation,” said Maha Guruswamy, Vice President & Managing Director, Commercial, Asia Pacific. “The challenge is that a traditional, individual-component system introduces significant technical and regulatory complexities. West Synchrony addresses these by providing a fully verified and integrated containment and delivery system from a single source, allowing our partners to accelerate development and focus on delivering therapies to patients.”

Deepening A Long-Term Partnership with China’s Pharmaceutical Ecosystem

The introduction of the West Synchrony™ PFS system reflects the company’s decades-long commitment to supporting pharmaceutical innovation. This investment extends beyond product offerings to include technical expertise, regulatory support, and a single source of accountability that serve both domestic Chinese companies and multinational partners operating in China.

“As China’s biopharmaceutical companies continue to strengthen their capabilities and expand their presence globally, West is committed to partnering with them at every stage of their growth journey,” said Philip Wang, Senior Director, Commercial, China. “We aim to enable them to achieve their global ambitions, and the West Synchrony™ PFS system is one example from our portfolio of high‑quality, innovative solutions that provide customers with the same trusted infrastructure relied upon by leading multinational pharmaceutical companies worldwide.”

Join West at CPHI & PMEC China 2026

The West Synchrony™ PFS system will be showcased at CPHI & PMEC China 2026, where an expert from West will present on the role of integrated delivery systems in supporting China’s next phase of biopharmaceutical innovation and its global ambitions for expansion. Trade media and industry stakeholders interested in learning more about the technology and its application in biologics are invited to visit the West booth during the exhibition. The details of the presentation are as follows:

Presentation: “Stop Piecing It Together—Get an Integrated Verified Prefillable Syringe System from One Source”

  • Date & Time: June 17, 14:10-14:40
  • Location: Shanghai New International Expo Center
  • Speaker: Lynn Yao, Senior Manager, TCS, AP
The West Synchrony™ PFS System is now available to bio and pharmaceutical companies in China. Visit West at Booth N5D18 to learn more, or find out more information via the website here.

Forward-Looking Statements

Certain forward-looking statements are included in this press release. They use words and phrases such as “achieving biotechnology breakthroughs,” “reaching global milestones,” “accelerate development,” and other similar terminology. These statements include, but are not limited to, statements regarding the anticipated benefits of the West Synchrony™ prefillable syringe system in China, the expected growth of China’s bio-health and pharmaceutical industries, and West’s ability to support customers’ development and commercialization efforts. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this release.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to, changes in market conditions, regulatory requirements, global economic and geopolitical conditions, customer demand, supply chain constraints, competitive developments, technological changes, and other risks. These important factors are not all inclusive. For a description of certain additional factors that could cause West’s future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled “Risk Factors,” in West’s Annual Report on Form 10-K for the year that ended on December 31, 2025. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.


1 Goldman Sachs, “China Is Increasing Its Share of Global Drug Development”, December 2025. https://www.goldmansachs.com/insights/articles/china-is-increasing-its-share-of-global-drug-development

Hashtag: #WestPharmaceuticalServices

The issuer is solely responsible for the content of this announcement.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 26 manufacturing facilities worldwide, West helps support its customers by delivering over 41 billion components and devices each year.

Headquartered in Exton, Pennsylvania, USA, West in its fiscal year 2025 generated USD 3.07 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit .

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries in the United States and other jurisdictions, unless otherwise noted.

Advertisements

Oil prices fell to three-month lows as a US-Iran framework to reopen the Strait of Hormuz and place Tehran’s enriched uranium stockpile under international control moved towards a planned June 19 signing in Geneva, easing fears of a deeper Gulf energy shock. Brent crude slipped to about $83 a barrel on Tuesday after a sharper fall at the start of the week, while West Texas Intermediate traded […]

Brussels has moved to assess the fallout from Washington’s order cutting foreign users off from Anthropic’s most powerful artificial intelligence models, turning a corporate shutdown into a test of allied trust in critical digital infrastructure. The European Commission is examining the practical consequences for users across the bloc after Anthropic disabled Fable 5 and Mythos 5, saying it had received a US export-control directive barring access by […]

Foreign investors delivered their strongest one-day purchase of Vietnamese equities in nearly six years on 15 June, signalling a sharp improvement in risk appetite after fears over Middle East energy disruption eased.

Overseas funds bought a net US$160.4 million of Vietnamese shares on Monday, the largest daily inflow since 10 September 2020. The buying helped steady a market that had been under pressure from rising oil prices, global risk aversion and sustained foreign withdrawals despite Vietnam’s long-awaited move towards emerging-market status.

The VN-Index rose 0.43 per cent to 1,799.31 on Monday and moved back above the 1,800-point area on Tuesday, keeping the benchmark close to levels that still represent a strong annual advance even after a pullback over the past month. The shift was part of a wider rebound across Asian emerging markets after the United States and Iran agreed on terms aimed at ending hostilities and reopening the Strait of Hormuz, easing concerns over inflation and fuel costs.

The reversal is notable because foreign investors have remained net sellers of Vietnamese equities this year. Even after Monday’s inflow, overseas funds have sold about US$2.6 billion of Vietnamese stocks in 2026, following withdrawals of roughly US$4.8 billion last year. Those outflows reflected concerns over market concentration, heavy exposure to a few large-cap groups, tariff uncertainty, currency pressure and the impact of higher energy prices on a manufacturing-led economy.

“De-escalation in the Middle East and Vietnam’s own underperformance have created a textbook re-entry set-up for foreign capital,” said Quynh Cao, head of institutional business at VNDirect Securities. “Positioning was already tight and it does not take much to flip that.”

Vietnam’s appeal to global investors rests on more than a single trading session. FTSE Russell has confirmed that the country will be reclassified from frontier to secondary emerging-market status from 21 September, with inclusion in global equity indices to be phased through 2027. The upgrade is expected to bring passive inflows of about US$1.5 billion, with broader active flows potentially lifting the total to several billion dollars if market reforms continue.

The reclassification follows changes aimed at improving foreign access, including the removal of full pre-funding requirements for equity trades and the development of a global broker model. These reforms address long-standing obstacles for institutional investors, who had complained about settlement risk, limited access channels and operational frictions that made Vietnam harder to replicate within global index portfolios.

Large-cap names expected to draw attention include Vingroup, Masan Group, FPT Corp and Hoa Phat Group, alongside banks, securities firms, industrial stocks and consumer companies with sufficient liquidity and foreign room. Average daily trading value in Vietnamese equities this year has been around US$789 million, underscoring the market’s growing depth, though liquidity remains uneven across sectors.

The macroeconomic backdrop remains supportive. Vietnam’s economy expanded 8.02 per cent in 2025, helped by strong exports, public investment, manufacturing activity and resilient consumption. Foreign direct investment disbursement rose to about US$27.6 billion last year, while exports reached roughly US$475 billion. Growth is expected to moderate this year, but projections still place Vietnam among Asia’s faster-growing economies.

Higher oil prices had complicated that outlook. Vietnam is exposed to imported fuel and energy costs, making any disruption in the Strait of Hormuz a direct risk to inflation, transport costs and factory margins. The drop in crude prices after the US-Iran accord helped restore confidence among investors looking at countries with strong structural growth but sensitivity to external shocks.

The market is not without vulnerabilities. Retail investors remain a major force in daily trading, making sentiment swings sharper when liquidity thins. Foreign ownership limits continue to constrain buying in some leading companies. Corporate governance, disclosure quality and settlement infrastructure also remain areas under watch as Vietnam seeks eventual MSCI emerging-market status.

Analysts say the latest inflow will need to be sustained before it can be treated as a durable turning point. A single large session can reflect short-covering, index positioning or tactical buying after a sell-off. A lasting reversal would require more consistent foreign participation, firmer currency conditions, stable oil prices and evidence that earnings growth can match valuations after the market’s strong run.

Dubai is preparing to award strategic contracts worth more than Dh55 billion for the expansion of Al Maktoum International Airport, marking a decisive step in turning Dubai World Central into the emirate’s main aviation gateway. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of The Executive Council of Dubai, said work on the airport expansion was progressing in line with the […]

Nintendo is facing an unverified data-extortion claim after a threat actor alleged it obtained nearly 859MB of employee-linked corporate records and demanded $2 million to prevent publication. The claim, attributed to an online actor using the handle SHADOWBYT3$, centres on data allegedly connected to TINYpulse, an employee engagement and feedback platform associated with WebMD Health Services. The material is said to include workforce survey records, corporate email […]

XRP held near $1.22 on Tuesday, stabilising after a bruising sell-off as extreme bearish commentary around the token began drawing attention from traders looking for a contrarian rebound. The token’s sideways move followed a modest recovery of about 4 per cent over the past week, a gain that stood out against a cautious wider cryptocurrency market. Bitcoin and Ether also traded firmer, but investor conviction remained fragile […]

Shoppers can stand to win S$10,000 daily exclusively on foodpanda when ordering from Sheng Siong, while enjoying islandwide delivery within an hour

SINGAPORE – Media OutReach Newswire – 16 June 2026 – foodpanda, Singapore’s leading food and grocery delivery platform, today announced a partnership with Sheng Siong, bringing one of the nation’s largest supermarket chains exclusively onto its platform for on-demand grocery delivery.

(From left) Peter Tan, Senior System Architect, Sheng Siong Group; Lin Zi Kai, Director of Customer and Operations, Sheng Siong Group; Lin Ruiwen, Executive Director, Sheng Siong Group; Bhavani Mishra, Managing Director, foodpanda Singapore; Ricky Davda, Head of Marketplace, foodpanda Singapore; and Yingchun Li, Head of Marketing & Growth, foodpanda Singapore, at the launch of foodpanda's partnership with Sheng Siong
(From left) Peter Tan, Senior System Architect, Sheng Siong Group; Lin Zi Kai, Director of Customer and Operations, Sheng Siong Group; Lin Ruiwen, Executive Director, Sheng Siong Group; Bhavani Mishra, Managing Director, foodpanda Singapore; Ricky Davda, Head of Marketplace, foodpanda Singapore; and Yingchun Li, Head of Marketing & Growth, foodpanda Singapore, at the launch of foodpanda’s partnership with Sheng Siong

From 22 June 2026, consumers can order more than 12,000 grocery products and household essentials from 43 Sheng Siong outlets islandwide, with plans to progressively onboard more outlets. Orders can be delivered in an hour, bringing Sheng Siong’s signature value and budget-friendly savings straight to the doorstep.

“As grocery delivery becomes part of everyday life for more Singapore households, consumers are looking for trusted brands, competitive prices and the convenience of shopping on their own terms,” said Bhavani Mishra, Managing Director of foodpanda Singapore. “Sheng Siong has earned the trust of generations of Singaporeans, and we are excited to welcome this beloved household brand onto foodpanda. By bringing together Sheng Siong’s trusted value with foodpanda’s convenience, we are making everyday grocery shopping even more accessible for consumers across Singapore.”

The partnership comes as demand for quick-commerce continues to grow in Singapore. foodpanda has seen grocery order frequency increase by 7% since 2023, while the average number of items per order has risen by 8%. This points to a broader shift in shopping habits, with more consumers relying on on-demand delivery not just for last-minute top-ups, but for their regular weekly grocery runs.

Strengthening foodpanda’s grocery ecosystem

Complementing foodpanda’s network of pandamart stores and existing grocery partners, Sheng Siong further strengthens the platform’s grocery offering and expands access to affordable options for Singapore households.

As grocery baskets continue to grow, foodpanda is also investing in fulfilment capabilities to support larger and bulkier orders. This includes a three-wheeler delivery fleet with increased carrying capacity to improve fulfilment efficiency, helping customers receive their weekly essentials quickly and reliably.

Through the partnership, consumers can look forward to:

  • Access to over 12,000 grocery and household products from Sheng Siong
  • On-demand doorstep delivery in an hour
  • Additional perks for pandapro subscribers, including free delivery on applicable orders

Lin Ruiwen, Executive Director, Sheng Siong Group, said,”At Sheng Siong, our focus has always been on providing quality products at competitive prices for Singapore households. As more consumers embrace the convenience of online grocery shopping, partnering with foodpanda allows us to extend that value proposition beyond our physical stores and better serve our consumer’s needs.”

Celebrating the launch with daily S$10,000 giveaways and exclusive savings

To celebrate the partnership, foodpanda and Sheng Siong are rolling out one of foodpanda’s biggest grocery campaigns to date, with S$280,000 total in cash prizes to be won.

From 22 June to 19 July 2026, customers who order from Sheng Siong on foodpanda will stand a chance to win S$10,000 in cash awarded to one winner each day throughout the campaign (terms and conditions apply).

Shoppers can also enjoy exclusive launch discounts on foodpanda, including:

  • Up to 40% off selected Sheng Siong products
  • Additional rewards and promotions throughout the campaign period

Hashtag: #foodpanda #grocery #shengsiong #partnership #singapore

The issuer is solely responsible for the content of this announcement.

About foodpanda Singapore

foodpanda is a leading on-demand delivery platform in Asia dedicated to bringing consumers a wide range of food, groceries and more, quickly and conveniently. Powered by technology and operational excellence, foodpanda is spearheading the growth of quick-commerce (q-commerce) across the region with its network of retail partners, as well as pandamart cloud stores to provide more on-demand options beyond the millions of food delivery options. foodpanda operates across 10 markets in Asia Pacific – Singapore, Hong Kong, Malaysia, Pakistan, Taiwan, Philippines, Bangladesh, Laos, Cambodia and Myanmar. foodpanda is a subsidiary of Delivery Hero, a global leader of the food delivery industry. For more information, visit .

Dubai WoodShow 2026 will open on June 22 with smart manufacturing technologies at the centre of a wider industry shift towards automated, data-led and materials-efficient production. The 22nd edition of the trade exhibition will run until June 24 at Dubai World Trade Centre, occupying Halls 6, 7 and 8 for a business-to-business audience spanning timber suppliers, machinery makers, furniture producers, fit-out contractors, architects, interior designers and building […]

Arabian Post Staff -Dubai Dubai will build 31 pedestrian bridges and tunnels across major corridors by 2030 under a five-year mobility plan aimed at cutting road risk, linking fast-growing communities and supporting a wider shift towards walking, cycling and e-scooter travel. The Roads and Transport Authority has approved the 2026-2030 programme after technical and field studies covering population density, land-use patterns, proximity to tourist and commercial districts, […]

Rise vGPU + ModelHub Power China’s AI into the Heterogeneous Orchestration Era

HONG KONG SAR – Media OutReach Newswire – 15 June 2026 – Frost & Sullivan, a globally renowned growth consulting firm, has released its “2026 AI Infrastructure Orchestration Platform White Paper”. The report recognizes Phancy Group’s Rise vGPU as a Tier 1 Leading Platform, the highest maturity tier in heterogeneous GPU orchestration. Phancy’s ModelHub also achieved the highest Overall Score in the enterprise-grade model management platform evaluation. This marks a significant endorsement of Phancy’s technological capability in heterogeneous AI infrastructure.

According to the white paper, as large model applications scale rapidly, China’s AI industry is facing structural challenges stemming from multi-chip coexistence. These include hardware heterogeneity, fragmented software stacks, persistently low GPU utilization (generally below 30%), and rising model adaptation complexity — all of which have become major bottlenecks for enterprise-scale AI deployment.

The report highlights a fundamental shift in AI infrastructure competitiveness – moving away from “single-chip performance” toward “cluster-scale system coordination.” At this critical juncture, Phancy has positioned itself as a leader in advanced orchestration through its full-stack AI infrastructure platform, offering a proven solution to heterogeneous compute challenges and helping drive China’s AI industry from “compute accumulation” into a new era of “compute orchestration.”

Phancy Rise vGPU: Tier 1 Leading Platform

In its assessment of mainstream AI infrastructure platforms, Frost & Sullivan defined Tier 1 criteria across three core dimensions: heterogeneous support, fine-grained control, and production-grade execution. Phancy Rise vGPU meets all three standards and has been recognized as a Tier 1 Leading Platform.

Rise vGPU transforms AI infrastructure from fragmented, low-efficiency device-level management to a unified software-defined control plane. Its key technology breakthroughs include:

  • Comprehensive Heterogeneous Management: Unified onboarding and management across more than 10 mainstream GPU/NPU vendors, including NVIDIA, Ascend, Cambricon, Hygon, and others.
  • Ultra-Fine Resource Partitioning: Industry-leading sub-GPU level compute and MB-level memory granularity slicing.
  • Significant Utilization Improvement: Through safe oversubscription and time/space multiplexing, GPU utilization is increased from industry averages below 30% to 70%-90%.
  • Intelligent Precision Scheduling: Multi-dimensional scheduling algorithms based on priority, topology, load, and resource awareness to achieve optimal compute allocation.
  • Production-Grade SLA Assurance: The Deterministic Execution Layer delivers committed and auditable SLA guarantees for critical inference workloads.
  • Full Lifecycle Operability: Comprehensive monitoring, metering, and cost allocation capabilities that turn GPU resources into truly operable digital assets.

Model Hub: Highest Overall Score in Model Management Platform Evaluation

Beyond compute orchestration, the report underscores the strategic importance of enterprise-grade model management platforms. As a powerful complement to Rise vGPU, Phancy ModelHub enables enterprises to build a complete full-stack AI infrastructure — from compute to models and from resource scheduling to business delivery.

The white paper notes that Phancy ModelHub delivers leading performance in key areas such as Model & Chip Compatibility, Execution Stability & Performance, and Model-GPU Coordination & Scheduling, achieving the highest Overall Score. Through its unified model management and execution platform, ModelHub creates a seamless closed-loop process covering model onboarding, deployment optimization, inference services, and version governance — significantly lowering the barrier to model deployment and accelerating AI innovation.

Dr. Dai Wenyuan, Founder & CEO of Phancy, said: “The Frost & Sullivan white paper accurately captures the inflection point in AI infrastructure development. The recognition of Rise vGPU as a Tier 1 Leading Platform and ModelHub’s top Overall Score provide important authoritative validation of Phancy’s technology strategy and product strength. As a full-stack AI cloud service platform, Phancy believes the next wave of competitiveness in the AI industry will come from systematic improvements in compute orchestration efficiency. We will continue to focus on heterogeneous compute unified scheduling and model ecosystem operations, working closely with customers and industry partners to advance China’s AI industry from ‘compute accumulation’ to a true ‘compute orchestration’ era.”

Hashtag: #PhancyGroup

The issuer is solely responsible for the content of this announcement.

About Phancy Group

Phancy Group (6682.HK) is a leading full-stack AI cloud services platform, providing comprehensive solutions for the AI 2.0 era. Our offerings include Rise vGPU, ModelHub and SageAIOS, delivering efficient and scalable AI infrastructure with end-to-end capabilities. We provide a complete solution from heterogeneous compute resource management and optimization to the deployment of intelligent agent models. These solutions empower digital transformation across a wide range of industries, supporting our vision of building a large-scale and efficient “Token Factory.”

Guided by the mission of “AI for Everyone” and positioned as the “Navigator of AI,” Phancy Group is committed to becoming a global leader in Artificial General Intelligence.

By Nitya Chakraborty Prime Minister Narendra Modi will be taking part in the outreach session of the 52nd meeting of G7 being held in Evans of France hosted by the French President Emanuel Macron. Already the main session started on Monday with the participation of the leaders of the seven nations. The main task of […]

The article Can PM Narendra Modi Redeem India’s Status As Defender Of Global South At G7 Meet In France? appeared first on Latest India news, analysis and reports on Newspack by India Press Agency).

Service provides medical assessment, ingredient information and delivery arrangements where appropriate

HONG KONG SAR – Media OutReach Newswire – 15 June 2026 – FastMed today announced the launch of online consultation support for hair loss concerns, providing a private and structured pathway for medical assessment of increased shedding, a receding hairline, thinning at the crown and reduced hair volume. The service covers online information submission, doctor assessment, review of possible hair loss causes, evidence-informed ingredient information and follow-up arrangements where appropriate.

Structured Online Assessment for Hair Loss Concerns

Hair loss has become an earlier concern among urban adults. Many cases are first managed through over-the-counter shampoos, hair growth serums, supplements or products promoted online. Hair loss, however, may be associated with a range of factors, including genetics, hormonal changes, stress, lack of sleep, nutritional status, scalp conditions, underlying illnesses and medication-related effects.

FastMed’s online consultation workflow supports the submission of relevant health information before medical assessment. Information reviewed may include duration of shedding, location of hair thinning, family history of hair loss, recent health status, lifestyle factors and products previously used. The process is designed to support assessment of whether hair loss may be related to temporary shedding, scalp-related concerns, or genetic and hormonal factors.

Genetic and Hormonal Factors Included in Assessment

Male-pattern hair loss, also known as androgenetic alopecia, and female-pattern hair loss are commonly associated with genetic and hormonal factors. These conditions may appear before middle age. Early signs may include a gradually receding frontal hairline, thinning at the crown, finer hair strands or widening of the hair parting. Because these changes often develop gradually, early signs may be mistaken for stress, insufficient rest or unsuitable haircare products.

Dr. Leung Kin Hei, medical adviser to FastMed, said: “Hair loss can involve a range of underlying causes. General haircare products may help cleanse the scalp or improve hair appearance, but hair loss associated with genetic or hormonal factors requires a clearer understanding of hair loss type and possible causes. A structured assessment process can support more appropriate follow-up decisions.”

Evidence-Informed Ingredient Information

FastMed’s online consultation support may also provide medical information on commonly discussed ingredients for hair loss, based on assessment findings. For androgenetic alopecia, ingredients commonly referenced in medical literature and supported by regulatory approval include finasteride and topical minoxidil. Finasteride is the active ingredient in prescription medicines such as Propecia and Damocare, while topical minoxidil is commonly found in external hair growth products such as Regro and Regaine.

Suitability, method of use and potential risks vary across ingredients. Prescription medicines in particular should only be considered following medical assessment. FastMed’s service is designed to support appropriate information provision and assessment-based follow-up, rather than product selection based solely on advertising, online reviews or brand claims.

Online Process Supports Privacy and Convenience

Hair loss is common, but concerns about appearance, confidence and privacy may delay medical support. FastMed’s online process allows information to be submitted through a digital pathway before doctor assessment. Where appropriate following assessment, the platform may arrange relevant support, medication advice, delivery or follow-up.

Dr. Leung added: “Hair loss concerns may affect confidence, social interaction and emotional well-being. Medical support is not intended to create anxiety. A structured assessment process can help clarify possible causes, reduce reliance on unverified online information and support more informed follow-up decisions.”

Hashtag: #FastMed #Medical #Health



The issuer is solely responsible for the content of this announcement.

About FastMed HK

FastMed is a medical platform providing online doctor consultations and delivery support. The platform supports access to appropriate medical information and follow-up arrangements in a private, convenient and compliant manner, with assessments conducted according to individual circumstances.

Arabian Post Staff -Dubai DMCC has rolled out a business acceleration package aimed at lowering costs, freeing cash flow and giving companies in its 26,000-plus member ecosystem more room to expand as competition for global trade and investment intensifies. The initiative offers licence renewal incentives, penalty waivers, administrative flexibility and set-up discounts for new entrants, positioning the Dubai business district to support established firms and companies weighing […]

Arabian Post Staff -Dubai Dubai has created a federal authority to steer artificial intelligence, public data and digital government policy under one national framework, marking a new phase in the country’s plan to embed autonomous systems across state services. HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President, Prime Minister of the UAE and Ruler of Dubai, approved the establishment of the Artificial Intelligence and Data Authority […]

Global peace has deteriorated for a 12th consecutive year as armed conflicts, military build-ups and geopolitical fragmentation deepen instability across much of the world, the 2026 Global Peace Index has found. The latest index, covering 163 countries and territories, recorded a 0.7 per cent decline in the average level of peacefulness over the past year, the 15th deterioration in 18 years. Ninety-nine countries became less peaceful, while […]

Arabian Post Staff -Dubai Abu Dhabi’s International Holding Company has begun an AED1.8 billion share repurchase, opening the first tranche of an approved AED5 billion buyback after a sharp rise in first-quarter profit and continued expansion across its investment portfolio. The initial purchase, launched on 12 June, represents 36 per cent of the total programme approved by shareholders at the company’s annual general assembly on 16 March […]

Africa’s top disease control agency has warned that the true scale of the Ebola outbreak in the Democratic Republic of Congo cannot be established because response teams have not located thousands of people exposed to confirmed patients. The Africa Centres for Disease Control and Prevention said contact tracing in Ituri, the outbreak’s epicentre, remains far below the level needed to break chains of transmission. Dr Jean Kaseya, […]

VISHNU RAJA
RYO YAMADA
HITORI GOTOH
IKUYO KITA